BIAF, BIAFW · CIK 0001712762 · operating
Based in San Antonio, Texas, bioAffinity Technologies develops non-invasive diagnostic tools for detecting early-stage lung cancer and other pulmonary diseases. The company's primary technology, CyPath lung, uses flow cytometry to analyze cell populations in sputum samples, identifying cancer-related cells shed from lung tumors. This approach enables detection without invasive procedures such as biopsies or imaging scans.
The company operates through two segments: Diagnostic Research and Development, which focuses on advancing its detection platform, and Laboratory Services, which delivers testing services to healthcare providers. Its diagnostic tools target the substantial clinical need for early lung cancer detection, particularly among high-risk populations.
bioAffinity Technologies operates with approximately 57 full-time employees and maintains its operations in the United States. The company was incorporated in Delaware in 2014 and trades on the Nasdaq exchange under the ticker BIAFW.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.75 | $-0.75 | +17.6% | |
| 2023 | $-0.91 | $-0.91 | +49.7% | |
| 2022 | — | $-1.81 | — |